(Q41609324)

English

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide

scientific article published on August 1997

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

1 reference

Europe PubMed Central

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

1 reference

based on heuristic

inferred from title

2

object named as

Jones RN

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Michael A. Pfaller

1

object named as

Pfaller MA

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

publication date

1 August 1997

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

157-163

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Survey of prevalence of extended spectrum beta-lactamases among enterobacteriaceae.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Meropenem: a microbiological overview

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter in vitro evaluation of SM-7338, a new carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro studies of meropenem

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase- and non-enzyme-mediated resistance to ampicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of meropenem, against gram-positive bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility of anaerobic bacteria to meropenem

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Origin and impact of plasmid-mediated extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions of meropenem with class I chromosomal beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900065-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(97)00065-5

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41609324&oldid=1959536276"